The world's first hexavalent rotavirus vaccine has completed its first dose in Wuhan.

On the 26th, it was learned from China National Pharmaceutical Group that the world's first oral hexavalent reconstituted rotavirus vaccine developed by China National Pharmaceutical Group's Wuhan Institute of Biological Products was successfully administered with its first dose in Wuhan. This marks an important breakthrough in the research and application of children's vaccines in China, injecting new momentum into the construction of a health protection system for children.